Wainua is approved to treat patients with hereditary transthyretin-mediated amyloid polyneuropathy and can be self-administered via an auto-injector.
The FDA has approved Wainua (eplontersen), an antisense medicine to treat patients living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a nerve disorder that results in the progressive loss of motor function. These patients accumulate TTR in other major organs, which compromises their function and eventually leads to death within five to 15 years of disease onset.
Developed by Ionis and AstraZeneca, Wainua is designed to reduce the production of transthyretin. It will be available in January 2024 and will be marketed by both companies in the United States. The companies did not release a price, but an AstraZeneca spokesperson said Wainua will be priced competitively and in line with its clinical benefit. Wainua is the only approved medicine to treat ATTRv-PN that can be self-administered via an auto-injector. Patients enrolled in a Medicare plan will access Wainua through Medicare Part D. AstraZeneca’s AZ&Me program will be able to help with out-of-pocket costs.
“Since 2008, the AZ&Me Prescription Savings Program has provided prescription assistance to more than 4 million patients in the United States and Puerto Rico,” the spokesperson said. AstraZeneca also has a program called AstraZeneca Access 360 to help navigate patients’ insurance coverage and direct patients to appropriate sources for financial assistance for which they may be eligible.
The approval is based on the positive 35-week interim analysis from the NEURO-TTRansform phase 3 trial, which showed patients treated with Wainua demonstrated consistent and sustained benefit on the co-primary endpoints of serum transthyretin (TTR) concentration and neuropathy impairment. Wainua achieved an 81.2% reduction in serum transthyretin (TTR) concentration from baseline, demonstrating reduced TTR protein production. Eplontersen demonstrated a favorable safety and tolerability profile.
The trial also demonstrated improvement in the key secondary endpoint of quality of life. Results from an analysis through week 85 were published in The Journal of the American Medical Association in September 2023.
Eplontersen is currently being evaluated in the CARDIO-TTRansform phase 3 trial to treat patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a systemic and progressive condition that typically leads to heart failure and often death within three-to-five years. This study has enrolled 1,400 patients, and results are expected in 2025.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More